Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Leukemia. 2019 May 23;33(12):2898–2911. doi: 10.1038/s41375-019-0489-6

Figure 5. Knockout of PRMT5 inhibits DLBCL growth both in vitro and in vivo.

Figure 5.

(A)Knockout of PRMT5 reduced symmetric dimethylation of histone H4R3. Immunoblot analysis of H4R3 dimethylation in the indicated cell lines after 6 days of PRMT5 sgRNA induction. β-actin served as a loading control. (B) Knockout of PRMT5 inhibited proliferation of DLBCL cells. Trypan blue dye exclusion viability assay of the indicated cell lines after 3 or 6 days of PRMT5 sgRNA induction. Error bars represent mean ± SD (*p<0.05, n=3). (C) Knockout of PRMT5 inhibited tumor growth in TMD8 and OCI-Ly7 xenograft mouse models. Error bars represent mean ± SD (*p<0.05, *** p<0.001, N=8).